Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Read more…
Leading industry expert with more than 25 years of experience in translation research in immunology Basel, Switzerland, 23 May 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director as of […]
Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases Dermatology industry veteran Thibaud Portal, PhD appointed as CEO London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which […]
Founded by Medicxi with Georgia Tech and UMass scientists, supported by US $30M investment from Medicxi Developing advanced, long-lasting therapies for dermatological diseases through radical new transepidermal delivery of proprietary siRNAs Led by dermatology veteran Thibaud Portal as CEO with a Scientific Advisory Board chaired by Nobel Prize Laureate, Craig Mello Boston, Massachusetts, March 16th, […]
Keele, UK, 15 June 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce two new appointments. Simon Greenhalgh has been appointed Group Chief Financial Officer (CFO) and Pete Webster takes up the position of UK […]